Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catequentinib added to platinum-based chemotherapy for platinum-resistant or platinum-refractory ovarian, fallopian tube, or primary peritoneal cancer
2024-516166-11-00Phase 3Authorised
- Sponsor
- Advenchen Laboratories
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised trial of catequentinib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Advenchen Laboratories. Primary endpoint: Progression-free survival. Planned start Jun 2022; status: authorised.
02
Drugs
catequentinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-516166-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516166-11-00.